WXXWY - WuXi Biologics (Cayman) Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
20.96
-0.16 (-0.75%)
At close: 3:35PM EDT
Stock chart is not supported by your current browser
Previous Close21.12
Open21.07
Bid0.00 x 0
Ask0.00 x 0
Day's Range20.39 - 21.07
52 Week Range11.56 - 21.85
Volume3,444
Avg. Volume16,825
Market Cap12.935B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Is WuXi Biologics (Cayman) Inc.'s (HKG:2269) 9.7% ROE Strong Compared To Its Industry?
    Simply Wall St.

    Is WuXi Biologics (Cayman) Inc.'s (HKG:2269) 9.7% ROE Strong Compared To Its Industry?

    One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

  • PR Newswire

    WuXi Biologics Reports Outstanding Interim Results

    52.4% Year-on-Year Revenue Growth to RMB1,607.1 Million Net Profit Increased 80.1% Year-on-Year to RMB449.5 Million Gross Profit Margin, Net Profit Margin and Adjusted Net Profit Margin All Record High ...

  • PR Newswire

    WuXi Biologics to Expand Integrated Biologics Conjugation Solution Center to Include Commercial Manufacturing

    WUXI, China , June 20, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...

  • WuXi Biologics Hosts Successful Inaugural Investor Day
    PR Newswire

    WuXi Biologics Hosts Successful Inaugural Investor Day

    WUXI, China, June 4, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced today that its Inaugural Investor Day, themed "Insights, Innovation & Acceleration", was held in Wuxi city on June 3, successfully attracting more than 200 international and domestic investors. Serving as an open and transparent communications channel, the event received great attention and active participation from the global investment community, proving to be another vital platform for investor communications in addition to the company's biannual result conferences in Hong Kong. For the first time, senior management at WuXi Biologics together presented the company's strengths and offerings to a number of investors, introducing in detail the integrated biologics technology platforms which enable organizations to discover, develop and manufacture biologics from concept to commercial manufacturing.

  • PR Newswire

    WuXi Biologics Signed Letter of Intent for Long-Term Vaccine Manufacturing Contract

    SHANGHAI, May 21, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it has entered into a strategic partnership Letter of Intent (LOI) with a global vaccine leader, pursuant to which WuXi Vaccines will build a dedicated facility and supply a commercial product for the global market. WuXi Vaccines is a joint venture company to be established between WuXi Biologics and Shanghai based Hile Bio-Technology (stock code 603718.SH).

  • WuXi Biologics Commenced Construction of a 48,000 L Integrated Manufacturing Center for Innovative Biologics in Chengdu
    PR Newswire

    WuXi Biologics Commenced Construction of a 48,000 L Integrated Manufacturing Center for Innovative Biologics in Chengdu

    The largest manufacturing center for biologics in Southwest China CHENGDU, China , May 16, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology ...

  • PR Newswire

    WuXi Biologics Successfully Completed First FDA Routine GMP Inspection

    SHANGHAI , April 17, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...

  • PR Newswire

    WuXi Biologics and I-Mab Biopharma Announce Long-term Strategic Manufacturing Partnership for Five Clinical and One Commercial Programs

    SHANGHAI, April 16, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and I-Mab Biopharma ("I-Mab"), a biotech company focusing exclusively on innovative biologics in immuno-oncology and auto-immune diseases, jointly announce today that the two companies have entered into a long-term strategic partnership on biologics process development, clinical and commercial manufacturing of I-Mab's highly innovative pipelines. Under the terms of the partnership, I-Mab will leverage WuXi Bio's expertise and capabilities for CMC development of at least five programs and commercial manufacturing of at least one program for its proprietary monoclonal antibody, bispecific antibody and fusion protein pipelines, representing a significant expansion from the current projects that the two companies are already collaborating on.

  • WuXi Biologics and NBE-Therapeutics Announce Comprehensive ADC Development and Manufacturing Partnership
    PR Newswire

    WuXi Biologics and NBE-Therapeutics Announce Comprehensive ADC Development and Manufacturing Partnership

    SHANGHAI and BASEL, Switzerland , April 9, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions ...

  • PR Newswire

    WuXi Biologics Wins 2019 CMO Leadership Awards in All Six Core Categories

    SHANGHAI and NEW YORK , April 3, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for ...

  • PR Newswire

    WuXi Biologics Receives "Asia's Best CMO of 2018" Award from IMAPAC

    SHANGHAI and SINGAPORE, March 26, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (Stock Code: 2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has received the "Asia's Best CMO of 2018" award from the consulting firm IMAPAC at the recent Asia-Pacific Bioprocessing Excellence Awards. The award was given to WuXi Biologics for the tremendous developments in its bioprocessing capabilities over the past year. "We are honored to be recognized by IMAPAC for the third time," said Dr. Chris Chen, CEO of WuXi Biologics.

  • Reuters

    BRIEF-Wuxi Biologics Cayman Announces Placing Existing Shares Of Co By Controlling Shareholder

    March 21 (Reuters) - Wuxi Biologics Cayman Inc: * ANNOUNCES PLACING OF 52 MILLION EXISTING SHARES OF CO BY CONTROLLING SHAREHOLDER AT A PRICE OF HK$77.00 EACH Source text for Eikon: Further company coverage:...

  • WuXi Biologics Receives EMA GMP Certificates
    PR Newswire

    WuXi Biologics Receives EMA GMP Certificates

    WuXi Biologics to be the first biologics company in China approved by both the U.S. FDA and EMA SHANGHAI and WUXI, China , March 19, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), ...

  • PR Newswire

    WuXi Biologics Continues to Deliver Record Results

    HONG KONG, March 18, 2019 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announces its audited annual results for the year ended December 31, 2018 today.

  • PR Newswire

    WuXi Biologics Congratulates Amicus on Receiving FDA Breakthrough Therapy Designation for AT-GAA

    - The second product successfully receiving Breakthrough Therapy Designation that WuXi Biologics has enabled its partner to develop SHANGHAI , Feb. 28, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") ...